03|17|26

4th Annual Brand Planning Report: Fueling Brand Plan Success Through AI‑Powered Integration 

In our fourth annual report, Chief Strategy Officer at EVERSANA INTOUCH, John Kenny, and Senior Partner of EVERSANA MANAGEMENT CONSULTING, Sean Rapson, explore the state of brand planning with input from pharma marketing executives, uncovering persistent gaps in efficiency, consistency, and the ability to harness data effectively. 

03|13|26

FDA Warning & Untitled Letters: What Pharma Marketers Need To Know 

The FDA’s recent untitled letters signal heightened scrutiny of promotional practices. Download the POV to learn what pharma marketers need to know, and how to proactively mitigate risk while staying compliant.

03|04|26

Rare Disease in Focus: How Innovation Is Accelerating Access for Patients

The rare disease landscape has long been defined by delay, with families frequently facing 7–10 years before receiving a diagnosis. In recognition of Rare Disease Day, Ann Cave, President, Full-Service Agency, wrote an article for PM360 spotlighting how innovation and human insight are reshaping the rare disease landscape.

03|02|26

Creative That Connects: Earning Trust in Rare Disease Communities

In honor of Rare Disease Day, Patrick Brodfuehrer penned an article in Med Ad News that explores what authentic connection really means for the 300 million people worldwide living with a rare disease.  

02|13|26

The “Pharma Bowl”: How Super Bowl 60 Became Pharma’s Biggest Stage

From GLP‑1 dominance to celebrity‑driven disease awareness, Super Bowl 60 marked a tipping point in how healthcare brands show up on the world’s biggest advertising stage. What was once considered a high‑risk investment is now a calculated brand‑building move, signaling a shift in how pharma thinks about cultural relevance, storytelling, and long‑term equity. 

01|30|26

Mind + Machine: How 2026 Brands Will Win the Future of Pharma Marketing 

In our recent webinar, leaders across strategy, creative, technology and omnichannel disciplines explored one essential question: How do 2026 brands win in a rapidly transforming healthcare ecosystem?

01|09|26

The Omnichannel Renaissance: What’s Next for Pharma in 2026? 

The life sciences industry is entering a new era. In a recent article penned for Med Ad News, Dan Gandor, EVP of Omnichannel Strategy, coined this the “Omnichannel Renaissance.”  

12|29|25

AI’s Next Big Move: Why Pharma Marketers Should Pay Attention

Artificial intelligence is changing the way people interact online, and the pace of innovation is accelerating. Just a few years ago, generative AI was a novelty. Today, platforms such as ChatGPT have become essential tools for millions, shaping how information is shared and decisions are made. At EVERSANA INTOUCH, we’re closely monitoring the next phase […]

12|22|25

DHC Monthly: What Pharma Marketers Should Act On for 2026 

The Digital Health Coalition’s December newsletter spotlights year‑end trends and predictions for 2026, featuring insights 18 industry leaders including Susan Perlbachs and Dan Gandor. Read the blog to learn about their key perspectives for 2026.

12|18|25

Beyond the Abstract: Four Converging Trends from ASH 2025

The American Society of Hematology (ASH) Annual Meeting is more than a forum for groundbreaking science; it is a barometer for the future of oncology. The key takeaways from ASH 2025 signal a fundamental shift in the hematologic cancer landscape, driven by a convergence of powerful forces. Download the POV to learn more.